MCID: KDN013
MIFTS: 31

Kidney Hypertrophy malady

Categories: Nephrological diseases

Aliases & Classifications for Kidney Hypertrophy

Aliases & Descriptions for Kidney Hypertrophy:

Name: Kidney Hypertrophy 12 14
Hypertrophy of Kidney 69

Classifications:



External Ids:

Disease Ontology 12 DOID:9622
ICD10 33 N28.81
ICD9CM 35 593.1
NCIt 47 C122991
SNOMED-CT 64 197800004 88531004
UMLS 69 C0156259

Summaries for Kidney Hypertrophy

MalaCards based summary : Kidney Hypertrophy, also known as hypertrophy of kidney, is related to vulvar sarcoma and atrophic vulva. An important gene associated with Kidney Hypertrophy is ALB (Albumin), and among its related pathways/superpathways are Lung fibrosis and TGF-beta receptor signaling (Pathway Interaction Database). The drugs Aspirin and Spironolactone have been mentioned in the context of this disorder. Affiliated tissues include kidney.

Related Diseases for Kidney Hypertrophy

Diseases related to Kidney Hypertrophy via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 49)
id Related Disease Score Top Affiliating Genes
1 vulvar sarcoma 10.2 ALB TGFB1
2 atrophic vulva 10.2 ALB TGFB1
3 retinal arterial macroaneurysm with supravalvular pulmonic stenosis 10.1 ALB NPHS1
4 miliaria 10.1 CTGF TGFB1
5 geleophysic dysplasia 2 10.1 CTGF TGFB1
6 anhidrosis 10.1 CTGF TGFB1
7 upper respiratory tract disease 10.1 CTGF TGFB1
8 hereditary night blindness 10.1 CTGF TGFB1
9 zika fever 10.1 CTGF TGFB1
10 cholera 10.1 CTGF TGFB1
11 pulmonary valve insufficiency 10.1 CTGF TGFB1
12 pigmentation disease 10.1 ALB ODC1 TGFB1
13 neuroectodermal endocrine syndrome 10.0 CTGF TGFB1
14 henoch-schoenlein purpura 10.0 ALB TGFB1
15 acute necrotizing encephalitis 10.0 ALB CTGF TGFB1
16 patent foramen ovale 10.0 ALB CTGF TGFB1
17 lymphoblastic lymphoma 10.0 ALB CTGF TGFB1
18 germ cell and embryonal cancer 10.0 CTGF TGFB1
19 pauci-immune glomerulonephritis 10.0 NPHS1 NPHS2
20 sick sinus syndrome 3 10.0 NPHS1 NPHS2
21 glaucoma 1, open angle, e 10.0 NPHS1 NPHS2
22 congenital torticollis 10.0 NPHS1 NPHS2
23 focal segmental glomerulosclerosis 10.0 NPHS1 NPHS2
24 frasier syndrome 10.0 NPHS1 NPHS2
25 lymphangiectasia, intestinal 10.0 CTGF TGFB1
26 benign secondary hypertension 9.9 NPHS2 TGFB1
27 deafness, autosomal recessive 51 9.9 NPHS1 NPHS2
28 hypothyroidism, congenital, nongoitrous, 3 9.9 NPHS1 NPHS2
29 albinism, oculocutaneous, type ia 9.9 CTGF TGFB1
30 malignant hyperthermia susceptibility 1 9.9 ALB NPHS1 NPHS2
31 hemiplegia 9.9 ALB NPHS1 NPHS2
32 acral persistent papular mucinosis 9.9 NPHS1 NPHS2
33 transient refractive change 9.9 ALB NPHS1 NPHS2
34 agammaglobulinemia 6 9.8 ALB CTGF NPHS1 TGFB1
35 lung giant cell carcinoma 9.8 ALB NPHS1 NPHS2
36 cerebral cavernous malformations-2 9.8 CTGF NPHS1 NPHS2
37 diprosopia 9.8 NPHS1 NPHS2 TGFB1
38 mixed germ cell-sex cord neoplasm 9.7 ALB NPHS1 NPHS2 TGFB1
39 familial nephrotic syndrome 9.7 ALB NPHS1 NPHS2 TGFB1
40 biliary cirrhosis, primary, 2 9.7 ALB NPHS1 NPHS2 TGFB1
41 heart valve disease 9.7 ALB NPHS1 NPHS2 TGFB1
42 hypertrichosis of eyelid 9.6 CTGF NPHS1 NPHS2 TGFB1
43 chronic pyelonephritis 9.5
44 pyelonephritis 9.5
45 bronchopneumonia 9.5
46 arteriosclerosis 9.5
47 uremia 9.5
48 calcinosis 9.5 ALB CTGF NPHS1 NPHS2 TGFB1
49 aphthous stomatitis 8.8 ALB ARAP1 CTGF NHEJ1 NPHS1 NPHS2

Comorbidity relations with Kidney Hypertrophy via Phenotypic Disease Network (PDN):


Acute Cystitis

Graphical network of the top 20 diseases related to Kidney Hypertrophy:



Diseases related to Kidney Hypertrophy

Symptoms & Phenotypes for Kidney Hypertrophy

Drugs & Therapeutics for Kidney Hypertrophy

Drugs for Kidney Hypertrophy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 186)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
2
Spironolactone Approved Phase 4,Phase 2 1952-01-7, 52-01-7 5833
3
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
4
Ticlopidine Approved Phase 4 55142-85-3 5472
5
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1 22916-47-8 4189
6
Everolimus Approved Phase 4,Phase 3,Phase 1 159351-69-6 6442177
7
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 1 53123-88-9 5284616 6436030 46835353
8
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492
9
Mycophenolic acid Approved Phase 4 24280-93-1 446541
10
Mycophenolate mofetil Approved, Investigational Phase 4 128794-94-5 5281078
11
Mivacurium Approved Phase 4 106791-40-6, 133814-19-4 5281042
12
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
13
Alendronate Approved Phase 4 121268-17-5, 66376-36-1 2088
14
Allopurinol Approved Phase 4 315-30-0 2094
15
Calcium carbonate Approved Phase 4 471-34-1
16
Chlorthalidone Approved Phase 4 77-36-1 2732
17
Azathioprine Approved Phase 4 446-86-6 2265
18
Cyclosporine Approved, Investigational, Vet_approved Phase 4 79217-60-0, 59865-13-3 5284373 6435893
19
Clopidogrel Approved, Nutraceutical Phase 4 120202-66-6, 113665-84-2 60606
20
Calcitriol Approved, Nutraceutical Phase 4 32222-06-3 134070 5280453
21 vitamin d Phase 4,Phase 2,Phase 3
22
Angiotensin II Phase 4,Phase 3,Phase 2 68521-88-0, 11128-99-7 65143 172198
23 diuretics Phase 4,Phase 2
24
Serotonin Phase 4 50-67-9 5202
25 Serotonin Agents Phase 4
26 Serotonin Uptake Inhibitors Phase 4
27 Natriuretic Agents Phase 4,Phase 2,Phase 1
28 Neurotransmitter Agents Phase 4,Phase 3
29 Neurotransmitter Uptake Inhibitors Phase 4
30 Hematinics Phase 4,Phase 3
31 Trace Elements Phase 4,Phase 2,Phase 3
32 Hormone Antagonists Phase 4,Phase 3,Phase 2
33 Hormones Phase 4,Phase 3,Phase 2
34 Diuretics, Potassium Sparing Phase 4,Phase 2
35 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2
36 Angiotensin II Type 1 Receptor Blockers Phase 4,Phase 3,Phase 2
37 Angiotensin Receptor Antagonists Phase 4,Phase 3,Phase 2
38 Angiotensinogen Phase 4,Phase 3,Phase 2
39 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4,Phase 3
40 Hypoglycemic Agents Phase 4,Phase 3
41 Anti-Bacterial Agents Phase 4,Phase 3,Phase 1
42 Vitamins Phase 4,Phase 2,Phase 3
43 Anti-Infective Agents Phase 4,Phase 3,Phase 1
44 Immunosuppressive Agents Phase 4,Phase 3,Phase 1
45 Antidepressive Agents Phase 4
46 Antifungal Agents Phase 4,Phase 3,Phase 1
47 Psychotropic Drugs Phase 4
48 Antihypertensive Agents Phase 4,Phase 3,Phase 2
49 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 1
50 Mineralocorticoid Receptor Antagonists Phase 4,Phase 2

Interventional clinical trials:

(show top 50) (show all 122)
id Name Status NCT ID Phase
1 Effects of Spironolactone in Dialysis Unknown status NCT01128101 Phase 4
2 Medical and Endovascular Treatment of Atherosclerotic Renal Artery Stenosis (METRAS Study) Unknown status NCT01208714 Phase 4
3 Major Depressive Disorder - Understanding The Link Between The Brain And The Heart Unknown status NCT01568307 Phase 4
4 A Morbidity-Mortality and Remodeling Study With Valsartan Unknown status NCT00133328 Phase 4
5 Do Xanthine Oxidase Inhibitors Reduce Both Left Ventricular Hypertrophy and Endothelial Dysfunction in Cardiovascular Patients With Renal Dysfunction? Completed NCT00688480 Phase 4
6 Does ALlopurinol Regress lefT Ventricular Hypertrophy in End Stage REnal Disease: The ALTERED Study Completed NCT01951404 Phase 4
7 Left Ventricular Hypertrophy and Spironolactone in End Stage Renal Disease Completed NCT00548912 Phase 4
8 EPO-BUL-01 - Study of the Optimization of Anemia Management of EPREX (Epoetin Alfa) in Predialysis Patients With Chronic Renal Failure Completed NCT00338000 Phase 4
9 Effect of Deep BLock on Intraoperative Surgical Conditions Completed NCT01631149 Phase 4
10 24 Months Follow-up, Two Arm Study to Compare the Cardiovascular Profile in a Regimen With Everolimus + Mycophenolic Acid (MPA) Versus (vs.) a Regimen of CNI+MPA in Maintenance Renal Transplant Recipients Completed NCT01169701 Phase 4
11 Parathyroidectomy in Endstage Renal Disease Completed NCT00745719 Phase 4
12 VIP: Vascular Imaging Project. Study on the Progression of Cardiovascular Disease in Renal Transplant Recipients Completed NCT00169910 Phase 4
13 Study of the Effect of Alendronate on Vascular Calcification and Arterial Stiffness in Chronic Kidney Disease Completed NCT00395382 Phase 4
14 Effect of Phosphate Binders on FGF-23 With Concurrent Calcitriol Completed NCT01748396 Phase 4
15 Effects of Strict Volume Control in Hypertensive Hemodialysis Patients on Cardiac Structure and Chronic Inflammation Completed NCT00307463 Phase 4
16 A Clinical Trial of IntensiVE Dialysis Completed NCT00649298 Phase 4
17 Comparison of Four and Eight Hours Dialysis Sessions in Thrice Weekly Hemodialysis Completed NCT00413803 Phase 4
18 Comparison of Post-dilution On-line Hemodiafiltration and Hemodialysis Completed NCT00411177 Phase 4
19 Effects of Everolimus in Left Ventricular Hypertrophy After Conversion From Azathioprine: A Pilot Study Recruiting NCT02493465 Phase 4
20 Comparing the Effects of Spironolactone With Chlortalidone on LV Mass in Patients With CKD Recruiting NCT02502981 Phase 4
21 Effects of Atorvastatin Treatment on Left Ventricular Diastolic Function in Peritoneal Dialysis Patients Recruiting NCT01503671 Phase 4
22 Effect of Etelcalcetide on Cardiac Hypertrophy in Hemodialysis Patients Not yet recruiting NCT03182699 Phase 4
23 Active Vitamin D Effect on Left Ventricular Hypertrophy Terminated NCT00175149 Phase 4
24 A Study to Assess the Safety and Efficacy of a Tacrolimus Based Immunosuppressive Regimen in Stable Kidney Transplant Recipients Converted From Cyclosporine Based Immunosuppressive Regimen Terminated NCT02963103 Phase 4
25 CLCNKA (Ka Renal Chloride Channel[ClC-Ka]) Polymorphism Effects on Hypertrophy Regression Withdrawn NCT01275352 Phase 4
26 Intranasal Steroids for the Treatment of Nocturnal Enuresis With Associated Obstructive Sleep Apnea Withdrawn NCT01861145 Phase 4
27 Vitamin D Supplementation and Cardiac Hypertrophy in Chronic Kidney Disease (CKD) Unknown status NCT01323712 Phase 2, Phase 3
28 Stenting of Renal Artery Stenosis in Coronary Artery Disease Study Unknown status NCT01173666 Phase 3
29 Triptolide-Containing Formulation as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD) Unknown status NCT02115659 Phase 3
30 Open-Label Extension of LOCKCYST Trial Unknown status NCT00771888 Phase 2, Phase 3
31 Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) Trial of Cardiovascular Events in High-Risk Hypertensive Patients Unknown status NCT00125463 Phase 3
32 The PRIMO Study: Paricalcitol Capsules Benefits Renal Failure Induced Cardiac Morbidity in Subjects With Chronic Kidney Disease Stage 3/4 Completed NCT00497146 Phase 3
33 The Effect of Epoetin Alfa on Cardiac Function and Quality of Life in Patients With Early Renal ((Kidney) Disease Completed NCT00446576 Phase 3
34 A Safety and Efficacy Study for Epoetin Alfa in Pre-dialysis Subjects. Completed NCT00364260 Phase 3
35 Effects of Somatostatin on ADPKD Heart Completed NCT02119013 Phase 2, Phase 3
36 Iron Sucrose in Stage 3/4 Kidney Disease Completed NCT00202345 Phase 3
37 Angiotensin-converting-enzyme (ACE) Inhibitors in Hemodialysis Completed NCT00985322 Phase 3
38 Medical Therapy of Prostatic Symptoms (MTOPS) Completed NCT00021814 Phase 3
39 Inflammatory Response to Salt in Essential Hypertension Completed NCT01665534 Phase 3
40 Effectiveness of Creatine Supplementation and Exercise on Muscle and Bone Completed NCT01057680 Phase 3
41 Effect of Strict Blood Pressure Control and ACE-Inhibition on Progression of Chronic Renal Failure in Pediatric Patients Completed NCT00221845 Phase 3
42 Cetrorelix Pamoate in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH) Completed NCT00663858 Phase 3
43 Combination of Metformine/Inulin Versus Metformin on Prostate Benign Hyperplasia in Metabolic Syndrome Completed NCT02778776 Phase 3
44 Effects of Losartan Versus Atenolol on Aortic and Cardiac Muscle Stiffness in Adults With Marfan Syndrome Completed NCT00723801 Phase 3
45 Octreotide in Severe Polycystic Liver Disease Completed NCT00426153 Phase 2, Phase 3
46 Lanreotide as Treatment of Polycystic Livers Completed NCT00565097 Phase 2, Phase 3
47 Pulsed Oral Sirolimus in Autosomal Dominant Polycystic Kidney Disease Recruiting NCT02055079 Phase 3
48 Lung Water by Ultrasound Guided Treatment in Hemodialysis Patients (The Lust Study). Recruiting NCT02310061 Phase 3
49 Renal Artery Denervation In Addition to Catheter Ablation To Eliminate Atrial Fibrillation Recruiting NCT01873352 Phase 3
50 The PRIMO II Study: Paricalcitol Injection Benefits in Renal Failure Induced Cardiac Morbidity in Subjects With Chronic Kidney Disease (CKD) Stage 5 Terminated NCT00616902 Phase 3

Search NIH Clinical Center for Kidney Hypertrophy

Genetic Tests for Kidney Hypertrophy

Anatomical Context for Kidney Hypertrophy

MalaCards organs/tissues related to Kidney Hypertrophy:

39
Kidney

Publications for Kidney Hypertrophy

Articles related to Kidney Hypertrophy:

(show all 23)
id Title Authors Year
1
Correlation of whole kidney hypertrophy with glomerular over-filtration in live, gender-mismatched renal transplant allografts. ( 27576505 )
2016
2
Stimulation of Sigma-1 receptor by dehydroepiandrosterone ameliorates hypertension-induced kidney hypertrophy in ovariectomized rats. ( 20404054 )
2010
3
Development of hypertension and kidney hypertrophy in transgenic mice overexpressing ARAP1 gene in the kidney. ( 16801480 )
2006
4
Renin-angiotensin system blockade prevents the increase in plasma transforming growth factor beta 1, and reduces proteinuria and kidney hypertrophy in the streptozotocin-diabetic rat. ( 15526251 )
2004
5
Effect of ammonium chloride and dietary phosphorus in the azotaemic rat. Part II--Kidney hypertrophy and calcium deposition. ( 15161952 )
2004
6
The juvenile three-spined stickleback (Gasterosteus aculeatus L.) as a model organism for endocrine disruption II--kidney hypertrophy, vitellogenin and spiggin induction. ( 15588642 )
2004
7
Neutralization of TGF-beta by anti-TGF-beta antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice. ( 8603776 )
1996
8
An evaluation of the role of polyamines in different models of kidney hypertrophy in mice. ( 7474658 )
1995
9
Inhibition of renal ornithine decarboxylase activity fails to reduce kidney size and urinary albumin excretion in diabetic rats with manifest kidney hypertrophy. ( 7796931 )
1995
10
Renal proteinases and kidney hypertrophy in experimental diabetes. ( 7926340 )
1994
11
Inhibition of renal ornithine decarboxylase activity prevents kidney hypertrophy in experimental diabetes. ( 8447376 )
1993
12
Transient increase in renal insulin-like growth factor binding proteins during initial kidney hypertrophy in experimental diabetes in rats. ( 1377139 )
1992
13
Morphometric analysis of kidney hypertrophy in rats after chronic potassium depletion. ( 1566879 )
1992
14
Vasopressin-dependent kidney hypertrophy: role of urinary concentration in protein-induced hypertrophy and in the progression of chronic renal failure. ( 2042645 )
1991
15
Characterization of beta-adrenergic receptor subtypes in androgen-induced mouse kidney hypertrophy using a new high-affinity ligand, [125I]iodocyanopindolol. ( 6299377 )
1983
16
Increased beta-adrenergic receptor complement in androgen-induced mouse kidney hypertrophy. ( 6269651 )
1981
17
Regulation of compensatory kidney hypertrophy by its own products. ( 894611 )
1977
18
The influence of salt intake on glomerular count in compensatory kidney hypertrophy in rats of different ages. ( 954972 )
1976
19
Ornithine decarboxylase activity and polyamine synthesis during kidney hypertrophy. ( 4119904 )
1972
20
Immunochemical studies on kidney hypertrophy of the rat. ( 13954727 )
1962
21
WEEKLY clinicopathological exercises: chronic pyelonephritis severe (with uremia); atrophy of the right kidney, hypertrophy of left; bronchopneumonia; aortic arteriosclerosis, severe, ascending arch, with short localized dissection; calcareous aortic stenosis. ( 14863577 )
1951
22
Kidney hypertrophy in B complex deficiency. ( 21024173 )
1946
23
THE PRODUCTION OF HYPERTENSION BY THE PREVENTION OF KIDNEY HYPERTROPHY: (Preliminary Report). ( 20321520 )
1939

Variations for Kidney Hypertrophy

Expression for Kidney Hypertrophy

Search GEO for disease gene expression data for Kidney Hypertrophy.

Pathways for Kidney Hypertrophy

Pathways related to Kidney Hypertrophy according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1 11.06 CTGF TGFB1
2 10.86 CTGF TGFB1
3 10.67 NPHS1 NPHS2 TGFB1
4 10.37 NPHS1 NPHS2

GO Terms for Kidney Hypertrophy

Cellular components related to Kidney Hypertrophy according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 platelet alpha granule lumen GO:0031093 8.96 ALB TGFB1
2 slit diaphragm GO:0036057 8.62 NPHS1 NPHS2

Biological processes related to Kidney Hypertrophy according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 excretion GO:0007588 9.16 NPHS1 NPHS2
2 T cell differentiation GO:0030217 8.96 NHEJ1 TGFB1
3 positive regulation of collagen biosynthetic process GO:0032967 8.62 CTGF TGFB1

Molecular functions related to Kidney Hypertrophy according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.28 ALB ARAP1 CTGF NHEJ1 NPHS1 NPHS2

Sources for Kidney Hypertrophy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....